Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: enzastaurin hydrochloride Clear all
Completed Phase 2 Interventional

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

NCT00105092
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Enzastaurin HCL
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Tampa, Florida • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2007 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia, Multiple Myeloma
Interventions
Enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

NCT00386087
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Enzastaurin Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Newark, Delaware • Indianapolis, Indiana • South Bend, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2008 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors

NCT00503724
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
enzastaurin hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

An Open Label Study of Oral Enzastaurin in Participants With Cancer

NCT00309140
View directory record Official record
Conditions
Neoplasms, Cancer
Interventions
enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00407758
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
enzastaurin hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
16
States / cities
Los Angeles, California • Chicago, Illinois • Decatur, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00308750
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
enzastaurin, pemetrexed, docetaxel, carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00052273
View directory record Official record
Conditions
Adult, Solid Tumor
Interventions
capecitabine, enzastaurin hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

NCT00452413
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Malignant Solid Tumor
Interventions
enzastaurin, erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

NCT00550927
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, enzastaurin hydrochloride, diagnostic laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer

NCT00530621
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
enzastaurin, placebo, pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Fayetteville, Arkansas • Lancaster, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

NCT03263026
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Enzastaurin Hydrochloride, R-CHOP + placebo
Drug · Other
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers

NCT00414960
View directory record Official record
Conditions
Lung Cancer
Interventions
Enzastaurin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 30, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

NCT03776071
View directory record Official record
Conditions
Glioblastoma
Interventions
Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy
Drug · Other · Radiation
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 30, 2026, 2:43 AM EDT